Ignite Creation Date:
2024-05-06 @ 8:11 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02686424
Status:
SUSPENDED
Last Update Posted:
2016-02-23
First Post:
2016-02-15
Brief Title:
Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy ONCO-RD 010 CRT
Sponsor:
Seoul National University Hospital
Organization:
Seoul National University Hospital
Study Overview
Official Title:
Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy
Status:
SUSPENDED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
paperwork delay
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ONCO-RD010CRT
Brief Summary:
Gastric cancer is one of the leading causes of cancer-related deaths worldwide Despite advances in therapeutic intervention the mortality from this disease remains high As a result most patients are now offered varying combinations of surgery chemotherapy and radiation therapy in order to derive benefits from a multidisciplinary approach Unfortunately therapies are often toxic or debilitating and therapeutic responses can vary Thus new therapeutic strategy is required for the treatment of gastric cancer
In the early 1980s the discovery of cytolytic T cells cytolytic T lymphocytes CTLs directed against an antigen presented on tumor cells was published They can kill many invasive cells by recognizing the tumor specific antigens on the major histocompatibility complex MHC molecules It is now generally agreed that although tumors express tumor antigens they usually lack immunogenicity because of their inability to activate the immune response The current view is that tumor cells are antigenic but not immunogenic If we can artificially activate the immune system against the tumor it may be possible to eradicate the tumor This approach is the basis of cancer immunotherapy
Many tumor antigens have been defined in terms of multiple solid tumors MART-1Melan-A gp100 carcinoembryonic antigen CEA HER-2 mucins ie MUC-1 prostate-specific antigen PSA and prostatic acid phosphatase PAP are just a short list Some immune-based therapies targeting these tumor antigens are in phase III trials assessing whether immunizing against these antigens affects overall survival In gastric cancer some tumor antigens such as MAGE-A3 NY-ESO-1 and WT-1 have been reported to be expressed in substantial proportion of cases They have the potential to be the targeting molecules for immunotherapy in the future In this study we aim to explore the expression levels of the four tumor markers MAGE-A3 NY-ESO-1 WT-1 and PRAME in gastric cancers of Korean patients and to examine the correlations of the expression levels of the four markers to clinic-patholoical factors
In the early 1980s the discovery of cytolytic T cells cytolytic T lymphocytes CTLs directed against an antigen presented on tumor cells was published They can kill many invasive cells by recognizing the tumor specific antigens on the major histocompatibility complex MHC molecules It is now generally agreed that although tumors express tumor antigens they usually lack immunogenicity because of their inability to activate the immune response The current view is that tumor cells are antigenic but not immunogenic If we can artificially activate the immune system against the tumor it may be possible to eradicate the tumor This approach is the basis of cancer immunotherapy
Many tumor antigens have been defined in terms of multiple solid tumors MART-1Melan-A gp100 carcinoembryonic antigen CEA HER-2 mucins ie MUC-1 prostate-specific antigen PSA and prostatic acid phosphatase PAP are just a short list Some immune-based therapies targeting these tumor antigens are in phase III trials assessing whether immunizing against these antigens affects overall survival In gastric cancer some tumor antigens such as MAGE-A3 NY-ESO-1 and WT-1 have been reported to be expressed in substantial proportion of cases They have the potential to be the targeting molecules for immunotherapy in the future In this study we aim to explore the expression levels of the four tumor markers MAGE-A3 NY-ESO-1 WT-1 and PRAME in gastric cancers of Korean patients and to examine the correlations of the expression levels of the four markers to clinic-patholoical factors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None